207 related articles for article (PubMed ID: 36528248)
1. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
2. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
5. Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.
Petrossian G; Ortiz J; Ortiz AC; Addonizio K; Hsiao A; James R; Koizumi N; Patel S; Plews R
Transpl Immunol; 2023 Aug; 79():101857. PubMed ID: 37201797
[TBL] [Abstract][Full Text] [Related]
6. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
7. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
9. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus.
Ge S; Chu M; Tang J; Kahwaji J; Karasyov A; Lovato D; Vo A; Choi J; Jordan SC; Zhang R; Toyoda M
Transpl Infect Dis; 2022 Apr; 24(2):e13805. PubMed ID: 35213773
[TBL] [Abstract][Full Text] [Related]
10. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
11. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
12. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
14. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
15. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
18. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
19. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up.
Schmitz R; Fitch ZW; Xu H; Ghali A; Mehta AK; Guasch A; Kirk AD
Am J Transplant; 2020 Dec; 20(12):3609-3619. PubMed ID: 32515087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
